We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Umbilical Cord Bilirubin Predicts Neonatal Jaundice

By LabMedica International staff writers
Posted on 17 Oct 2017
Hyperbilirubinemia is one of the commonest causes of admission to hospital in the neonatal period amongst term babies in all settings. Prevention of serious complications depends on effective early treatment, but clinically significant jaundice may not develop until one or more days after delivery.

Identification of biomarkers that could be measured within a few hours following birth, which robustly predict incident jaundice, would represent a significant advance. Estimation of umbilical cord blood bilirubin (UCB) at delivery is practicable, cheap and non-invasive. It could be easily integrated with the current trend towards routine umbilical cord blood biochemical evaluation practiced in many centers.

Neonatal specialists at Homerton University Hospital (London, UK) carried out a retrospective analysis of hospital biochemistry records identified term deliveries with recorded arterial UCB (aUCB). Infant medical records were reviewed to identify those who developed neonatal hyperbilirubinemia requiring treatment according to UK NICE guidelines, with/without a positive direct antiglobulin test (DAT). Over the 9-month period, there were 4,069 inborn deliveries, on who umbilical cord blood analysis had been performed on 2,128 (52.2%). The neonatal unit is equipped with a GEM 4000 whole blood analyzer, which automatically provides total bilirubin estimation on samples.

Of 1,411 term deliveries with a clearly recorded aUCB, 30 infants developed clinically significant jaundice (2.7%), of whom eight were DAT + ve (0.6%) mostly due to ABO incompatibility. aUCB strongly predicted the development of DAT + ve jaundice, as well as all-cause jaundice. However, this effect was critically dependent on maternal blood group. Amongst infants at risk of ABO incompatibility (maternal blood groups O+ve/O-ve, 39.7%) the predictive value of aUCB for all cause jaundice was strengthened. Amongst those not at risk (defined maternal blood group not O+ve/O-ve, 51.0%) it disappeared completely. A cutoff of 35 μmol/L for mothers with blood group O+ve/O-ve increased the pre-test probability for all-cause jaundice of 4% to a post-test probability of 30%.

The authors concluded that for infants of mothers with blood group O, aUCB predicts development of neonatal jaundice. There was no evident utility for infants of mothers with other blood groups. Estimation of aUCB should be considered as a strategy for early identification of those at risk of neonatal hemolytic jaundice. The study was published on September 20, 2017, in the journal BMC Pediatrics.

Related Links:
Homerton University Hospital


Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Immunofluorescence Analyzer
MPQuanti
New
Biological Indicator Vials
BI-O.K.
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The study investigated D-dimer testing in patients who are at higher risk of pulmonary embolism (Photo courtesy of Adobe Stock)

D-Dimer Testing Can Identify Patients at Higher Risk of Pulmonary Embolism

Pulmonary embolism (PE) is a commonly suspected condition in emergency departments (EDs) and can be life-threatening if not diagnosed correctly. Achieving an accurate diagnosis is vital for providing effective... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.